Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen.

Savelyeva N, Shipton M, Suchacki A, Babbage G, Stevenson FK.

Blood. 2011 Jul 21;118(3):650-9. doi: 10.1182/blood-2011-01-328864. Epub 2011 May 25.

2.

Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.

Savelyeva N, King CA, Vitetta ES, Stevenson FK.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10987-92. Epub 2005 Jul 21.

3.

BASH-deficient mice: limited primary repertoire and antibody formation, but sufficient affinity maturation and memory B cell generation, in anti-NP response.

Yamamoto M, Nojima T, Hayashi K, Goitsuka R, Furukawa K, Azuma T, Kitamura D.

Int Immunol. 2004 Aug;16(8):1161-71. Epub 2004 Jul 5.

4.

Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue.

Shimoda M, Nakamura T, Takahashi Y, Asanuma H, Tamura S, Kurata T, Mizuochi T, Azuma N, Kanno C, Takemori T.

J Exp Med. 2001 Dec 3;194(11):1597-607.

5.

Antiviral B cell memory in the absence of mature follicular dendritic cell networks and classical germinal centers in TNFR1-/- mice.

Karrer U, López-Macías C, Oxenius A, Odermatt B, Bachmann MF, Kalinke U, Bluethmann H, Hengartner H, Zinkernagel RM.

J Immunol. 2000 Jan 15;164(2):768-78.

6.

MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production.

Munthe LA, Os A, Zangani M, Bogen B.

J Immunol. 2004 Jun 15;172(12):7476-84. Erratum in: J Immunol. 2005 Nov 1;175(9):6235.

7.

Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors.

Horikawa K, Martin SW, Pogue SL, Silver K, Peng K, Takatsu K, Goodnow CC.

J Exp Med. 2007 Apr 16;204(4):759-69. Epub 2007 Apr 9.

8.

Human immunoglobulin (IgG) induced deletion of IgM rheumatoid factor B cells in transgenic mice.

Tighe H, Heaphy P, Baird S, Weigle WO, Carson DA.

J Exp Med. 1995 Feb 1;181(2):599-606.

9.

SAP is required for generating long-term humoral immunity.

Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R.

Nature. 2003 Jan 16;421(6920):282-7.

PMID:
12529646
10.
11.

Tolerance induction of IgG+ memory B cells by T cell-independent type II antigens.

Haniuda K, Nojima T, Ohyama K, Kitamura D.

J Immunol. 2011 May 15;186(10):5620-8. doi: 10.4049/jimmunol.1100213. Epub 2011 Apr 13.

12.
13.

Memory B cells at successive stages of differentiation. Affinity maturation and the role of IgD receptors.

Herzenberg LA, Black SJ, Tokuhisa T, Herzenberg LA.

J Exp Med. 1980 May 1;151(5):1071-87.

14.

A genetic approach to idiotypic vaccination for B cell lymphoma.

Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Thompsett A, Hawkins RE.

Ann N Y Acad Sci. 1995 Nov 27;772:212-26. Review.

PMID:
8546396
15.

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ.

J Immunother. 2011 Jan;34(1):1-15. doi: 10.1097/CJI.0b013e3181f7dbe8.

PMID:
21150709
16.

Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.

Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.

J Clin Immunol. 2007 Jan;27(1):117-30. Epub 2006 Dec 16.

PMID:
17180470
17.

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

Hu HM, Winter H, Urba WJ, Fox BA.

J Immunol. 2000 Oct 15;165(8):4246-53.

18.

DNA fusion gene vaccines against cancer: from the laboratory to the clinic.

Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D.

Immunol Rev. 2004 Jun;199:156-80. Review.

PMID:
15233733
19.

B-cell influences on the induction of allotype suppressor T cells.

Black SJ, Herzenberg LA.

J Exp Med. 1979 Jul 1;150(1):174-83.

20.

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.

Cancer Res. 2001 Feb 1;61(3):880-3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk